Ewa Gorczyńska

Ewa Gorczyńska

Auto-generated profile, based on publicly available information

Ewa Gorczyńska

Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology Wroclaw Medical University Wroclaw Poland

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2012 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
KDKatarzyna Drabko
Katarzyna Drabko
ARAnna Raciborska
Anna Raciborska
KBK Bilska
K Bilska
JSJan Styczyński
Jan Styczyński
Marek UssowiczMarek Ussowicz
Marek Ussowicz
JKJerzy Roman Kowalczyk
Jerzy Roman Kowalczyk

1 August 1996 in Pflügers Archiv - European Journal of Physiology
Verified
Journal Article
Closed access
PDF file
EGE. Gorczynska
E. Gorczynska
PHP. L. Huddie
P. L. Huddie
BMB. A. Miller
B. A. Miller
IMIan Mellor
Ian Mellor
HVH. Vais
H. Vais
PUP. N. R. Usherwood
P. N. R. Usherwood

18 September 2020 in Pediatric Transplantation
Verified
Journal Article
Open access
PDF file
TJTomasz Jarmoliński
Tomasz Jarmoliński
AMAgnieszka Matkowska–Kocjan
Agnieszka Matkowska–Kocjan
MRMonika Rosa
Monika Rosa
IOIgor Olejnik
Igor Olejnik
EGEwa Gorczyńska
Ewa Gorczyńska
Marek UssowiczMarek Ussowicz
Marek Ussowicz
Respiratory viral infections are known causes of mortality after allogeneic hematopoietic stem cell transplantation (HSCT). Here, we report a unique case of a child with viral pneumonia caused by coinfection with human metapneumovirus (MPV), respiratory syncytial virus (RSV), and SARS‐CoV‐2 after HSCT. A 9‐year‐old girl with acute lymphoblastic leukemia underwent allogeneic HSCT from a matched, unrelated donor. During the post‐transplant period, in profound leukopenia (below 10 leukocytes/µL), she was diagnosed with SARS‐CoV‐2, MPV, and RSV pneumonia and was treated with ribavirin and chloroquine. Before leukocyte recovery, the girl became asymptomatic, and SARS‐CoV‐2 and RSV clearance was achieved. The shedding of SARS‐CoV‐2 stopped before immune system recovery, and one may hypothesize that the lack of an inflammatory response might have been a contributing factor to the mild clinical course. Post‐transplant care in HSCT recipients with COVID‐19 infection is feasible in regular transplant units, provided the patient does not present with respiratory failure. Early and repeated testing for SARS‐CoV‐2 in post‐transplant patients with concomitant infection mitigation strategies should be considered in children after HSCT who develop fever, respiratory symptoms, and perhaps gastrointestinal symptoms to control the spread of COVID‐19 both in patients and in healthcare workers in hospital environments. Training of staff and the availability of personal protective equipment are crucial for containing SARS‐CoV‐2 infection.

13 October 2014 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
JGJ Gozdzik
J Gozdzik
KRK Rewucka
K Rewucka
AKAleksandra Krasowska-Kwiecień
Aleksandra Krasowska-Kwiecień
APA Pieczonka
A Pieczonka
RDR Debski
R Debski
JWJ Wachowiak
J Wachowiak

24 March 2020 in Advances in Clinical and Experimental Medicine
Verified
Journal Article
Open access
ZSZofia Szmit
Zofia Szmit
KKKrzysztof Kałwak
Krzysztof Kałwak
MMMonika Mielcarek-Siedziuk
Monika Mielcarek-Siedziuk
Marek UssowiczMarek Ussowicz
Marek Ussowicz
JOJoanna Owoc-Lempach
Joanna Owoc-Lempach
EGEwa Gorczyńska
Ewa Gorczyńska
Background. Hepatic veno-occlusive disease (VOD) is a life-threatening complication following hematopoietic stem cell transplantation (HSCT) and associated with a high mortality rate. Therefore, accurate and immediate diagnosis is crucial for implementing appropriate treatment. Objectives. In our single-center retrospective study, we assessed the accuracy of the Modified Seattle Criteria in children and adolescents undergoing HSCT, and compared them to the diagnostic criteria recently established by the European Society for Blood and Marrow Transplantation (EBMT). Material and methods. Retrospective analysis of medical records of 951 HSCT procedures performed in 850 children and young adults in the years 2001-2015 in the Department of Pediatric Hematology, Oncology and Bone Marrow Transplantation of Wroclaw Medical University Supraregional Center of Pediatric Oncology "Cape of Hope" in Wroclaw, Poland. Results. Among the 850 children, 48 were diagnosed with VOD according to the Modified Seattle Criteria (5.05%). Thirteen patients (27%) developed VOD later than within 20 days after transplantation, as required in the diagnostic criteria. Five of the 6 patients who died from VOD were diagnosed with late-onset VOD. Using the categories of symptoms described in the Modified Seattle Criteria, hepatomegaly and weight gain were the most common symptoms in the analyzed cohort (81.25% and 68.75%). Fourteen patients (29%) never demonstrated elevated plasma bilirubin level (>2 mg/dL), as suggested in the Modified Seattle Criteria. Twenty-nine patients (64%) had increased platelet consumption requiring daily transfusions. Only 5 patients with decreased plasma antithrombin III (ATIII) activity level (<80%) on the day of HSCT developed VOD despite supplementation of ATIII. Conclusions. The Modified Seattle Criteria seemed to not meet the special needs of the pediatric population. The new diagnostic criteria proposed by the EBMT appear to be more adequately tailored to the pediatric population and may significantly change the conception of VOD in the future. The surprisingly low incidence of VOD in our cohort may suggest a beneficial role of monitoring and early supplementation of ATIII.

19 August 2019 in Advances in Clinical and Experimental Medicine
Verified
Journal Article
Open access
EWElżbieta Wawrzyniak-Dzierżek
Elżbieta Wawrzyniak-Dzierżek
KGKornelia Gajek
Kornelia Gajek
ŚAŚlęzak Aleksandra
Ślęzak Aleksandra
BRBlanka Rybka
Blanka Rybka
RRRyczan-Krawczyk Renata
Ryczan-Krawczyk Renata
Marek UssowiczMarek Ussowicz
Marek Ussowicz
Background. Unmanipulated haploidentical stem cell transplantation (haploSCT) with post-transplant cyclophosphamide is an option for patients with advanced hematologic malignancies. It offers a platform both for non-major histocompatibility complex-restricted alloimmunity due to killer-like immunoglobulin receptor (KIR)-mediated mechanisms of natural killer lymphocyte regulation and for classical T-cell mediated antileukemic effects. Objectives. The devastating long-term sequelae after total body irradiation (TBI) in children are encouraging omission of irradiation techniques in pediatric stem cell transplantations (SCT). Material and methods. Five children, 4 with acute leukemia and 1 with hemophagocytic lymphohistiocytosis, aged from 1 to 10 years, underwent haploSCT with post-transplantation cyclophosphamide. In all children, the conditioning regimen consisted of chemotherapy without TBI. The graft material was bone marrow (BM) in 4 cases and peripheral blood stem cells in 1 case. Three out of 5 leukemic patients showed better KIR haplotype associated with augmented alloreactivity. Results. Engraftment with complete donor chimerism was achieved in 4 patients, and 1 recipient died before leukocyte recovery. Three patients developed skin acute graft-versus-host-disease (aGvHD), 1 gut aGvHD and 1 liver aGvHD. In 2 recipients, chronic graft-versus-host-disease (cGvHD) was observed (1 limited and 1 extensive). The 4 engrafted patients were alive and in complete remission 3, 9, 32, and 36 months after transplantation. A T-cell count of 200 cells/uL was reached 90 days after haploSCT in all patients. Conclusions. HaploSCT with TBI-free protocols can be a viable option for heavily pretreated patients with advanced malignancies.